» Articles » PMID: 37554763

Self-assembled GLP-1/glucagon Peptide Nanofibrils Prolong Inhibition of Food Intake

Overview
Specialty Endocrinology
Date 2023 Aug 9
PMID 37554763
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Oxyntomodulin (Oxm) hormone peptide has a number of beneficial effects on nutrition and metabolism including increased energy expenditure and reduced body weight gain. Despite its many advantages as a potential therapeutic agent, Oxm is subjected to rapid renal clearance and protease degradation limiting its clinical application. Previously, we have shown that subcutaneous administration of a fibrillar Oxm formulation can significantly prolong its bioactivity from a few hours to a few days.

Methods: We used a protease resistant analogue of Oxm, Aib2-Oxm, to form nanfibrils depot and improve serum stability of released peptide. The nanofibrils and monomeric peptide in solution were characterized by spectroscopic, microscopic techniques, potency assay, QCM-D and studies.

Results: We show that in comparison to Oxm, Aib2-Oxm fibrils display a slower elongation rate requiring higher ionic strength solutions, and a higher propensity to dissociate. Upon subcutaneous administration of fibrillar Aib2-Oxm in rodents, a 5-fold increase in bioactivity relative to fibrillar Oxm and a significantly longer bioactivity than free Aib2-Oxm were characterized. Importantly, a decrease in food intake was observed up to 72-hour post-administration, which was not seen for free Aib2-Oxm.

Conclusion: Our findings provides compelling evidence for the development of long-lasting peptide fibrillar formulations that yield extended plasma exposure and enhanced pharmacological response.

Citing Articles

Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity.

Zhang J, Wei J, Lai W, Sun J, Bai Y, Cao H Int J Mol Sci. 2025; 26(4).

PMID: 40004115 PMC: 11855704. DOI: 10.3390/ijms26041651.


Principles and Biomedical Applications of Self-Assembled Peptides: Potential Treatment of Type 2 Diabetes Mellitus.

Mohammad Karim A Pharmaceutics. 2024; 16(11).

PMID: 39598565 PMC: 11597675. DOI: 10.3390/pharmaceutics16111442.

References
1.
Pocai A . Action and therapeutic potential of oxyntomodulin. Mol Metab. 2014; 3(3):241-51. PMC: 3986661. DOI: 10.1016/j.molmet.2013.12.001. View

2.
Buell A, Dobson C, Welland M . Measuring the kinetics of amyloid fibril elongation using quartz crystal microbalances. Methods Mol Biol. 2012; 849:101-19. DOI: 10.1007/978-1-61779-551-0_8. View

3.
Henderson S, Konkar A, Hornigold D, Trevaskis J, Jackson R, Fritsch Fredin M . Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab. 2016; 18(12):1176-1190. PMC: 5129521. DOI: 10.1111/dom.12735. View

4.
Demizu Y, Doi M, Kurihara M, Okuda H, Nagano M, Suemune H . Conformational studies on peptides containing α,α-disubstituted α-amino acids: chiral cyclic α,α-disubstituted α-amino acid as an α-helical inducer. Org Biomol Chem. 2011; 9(9):3303-12. DOI: 10.1039/c0ob01146k. View

5.
Wynne K, Park A, Small C, Patterson M, Ellis S, Murphy K . Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes. 2005; 54(8):2390-5. DOI: 10.2337/diabetes.54.8.2390. View